Clinical trial
Vaccine Therapy in Treating Patients With Melanoma
NCT00020358 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00020358 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Melanoma |
| Official title | Randomized Comparison of Three Schedules of Peptide Immunization in Patients With Stage II or III, or Completely Resected Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, gp100 antigen, incomplete Freund's adjuvant, tyrosinase peptide |
| Start date | Sep 1, 2000 |
| Completion | Oct 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: